A detailed history of Price T Rowe Associates Inc transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,313,305 shares of RVMD stock, worth $230 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,313,305
Previous 5,216,659 1.85%
Holding current value
$230 Million
Previous $202 Million 19.02%
% of portfolio
0.03%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.92 - $47.94 $3.57 Million - $4.63 Million
96,646 Added 1.85%
5,313,305 $241 Million
Q2 2024

Aug 14, 2024

BUY
$30.14 - $40.68 $12.1 Million - $16.4 Million
402,349 Added 8.36%
5,216,659 $202 Million
Q1 2024

May 15, 2024

BUY
$26.56 - $33.55 $4.73 Million - $5.97 Million
177,957 Added 3.84%
4,814,310 $155 Million
Q4 2023

Feb 14, 2024

SELL
$18.35 - $34.12 $8.41 Million - $15.6 Million
-458,353 Reduced 9.0%
4,636,353 $133 Million
Q3 2023

Nov 14, 2023

BUY
$25.17 - $35.05 $1.91 Million - $2.66 Million
75,941 Added 1.51%
5,094,706 $141 Million
Q2 2023

Aug 14, 2023

SELL
$20.28 - $27.0 $332,875 - $443,178
-16,414 Reduced 0.33%
5,018,765 $134 Million
Q1 2023

May 15, 2023

BUY
$20.76 - $30.09 $28.1 Million - $40.8 Million
1,355,137 Added 36.82%
5,035,179 $109 Million
Q4 2022

Feb 14, 2023

BUY
$17.68 - $25.53 $484,679 - $699,879
27,414 Added 0.75%
3,680,042 $87.7 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $24.7 Million - $36.8 Million
1,414,774 Added 63.22%
3,652,628 $72 Million
Q2 2022

Aug 15, 2022

SELL
$14.54 - $27.17 $900,927 - $1.68 Million
-61,962 Reduced 2.69%
2,237,854 $43.6 Million
Q1 2022

May 16, 2022

BUY
$17.31 - $26.4 $21.5 Million - $32.8 Million
1,244,045 Added 117.83%
2,299,816 $58.7 Million
Q4 2021

Feb 14, 2022

BUY
$24.35 - $33.7 $874,773 - $1.21 Million
35,925 Added 3.52%
1,055,771 $26.6 Million
Q3 2021

Nov 15, 2021

BUY
$23.95 - $33.41 $24 Million - $33.5 Million
1,001,922 Added 5589.83%
1,019,846 $28.1 Million
Q2 2021

Aug 16, 2021

BUY
$29.0 - $47.44 $59,421 - $97,204
2,049 Added 12.91%
17,924 $569,000
Q1 2021

May 17, 2021

SELL
$37.21 - $54.43 $2.86 Million - $4.19 Million
-76,945 Reduced 82.9%
15,875 $728,000
Q4 2020

Feb 16, 2021

BUY
$30.19 - $45.49 $2.8 Million - $4.22 Million
92,820 New
92,820 $3.68 Million

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.